



AMERICAN ACADEMY™  
OF OPHTHALMOLOGY

11

---

## Lens and Cataract

---

*Last major revision 2016–2017*

2017–2018  
**BCSC**  
Basic and Clinical  
Science Course™

Protecting Sight. Empowering Lives.™



Published after collaborative  
review with the European Board  
of Ophthalmology subcommittee

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2019. AMA PRA Category 1 Credits™ may be claimed only once between June 1, 2016, and the expiration date.

BCSC® volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim AMA PRA Category 1 Credits™ upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 11 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. **The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, *Ophthalmology*, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, *Neuro-Ophthalmology*. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved.  
No part of this publication may be reproduced without written permission.

Printed in the United States of America.

# Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

## Section 11

---

### Faculty

Sharon L. Jick, MD, *Chair*, St Louis, Missouri

Thomas L. Beardsley, MD, Asheville, North Carolina

Chadwick R. Brasington, MD, Burlington, North Carolina

Carlos Buznego, MD, Miami, Florida

Richard J. Grostern, MD, Chicago, Illinois

Lisa Park, MD, New York, New York

Timothy V. Roberts, MD, *Consultant*, Sydney, Australia

The Academy wishes to acknowledge the *American Society of Cataract and Refractive Surgery* and the *Contact Lens Association of Ophthalmologists* for recommending faculty members to the BCSC Section 11 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

*Committee on Aging*: Tim Johnson, MD, Iowa City, Iowa

*Vision Rehabilitation Committee*: John D. Shepherd, MD, Omaha, Nebraska

*Practicing Ophthalmologists Advisory Committee for Education*: Edward K. Isbey III, MD, *Primary Reviewer* and *Chair*, Asheville, North Carolina; Alice Bashinsky, MD, Asheville, North Carolina; David Browning, MD, PhD, Charlotte, North Carolina; Bradley Fouraker, MD, Tampa, Florida; Dasa Gangadhar, MD, Wichita, Kansas; Steven J. Grosser, MD, Golden Valley, Minnesota; Stephen R. Klapper, MD, Carmel, Indiana; James A. Savage, MD, Memphis, Tennessee



*European Board of Ophthalmology*: Béatrice Cochener-Lamard, MD, PhD, *Chair*, Brest, France; Marie-José Tassignon, MD, PhD, *Liaison*, Edegem, Belgium; Roberto Bellucci, MD, Salò, Italy; Simonetta Morselli, MD, Verona, Italy; Zoltan Nagy, MD, Budapest, Hungary

## **Financial Disclosures**

Academy staff members who contributed to the development of this product state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had the following financial relationships:\*

Dr Bellucci: Bausch + Lomb Surgical (C), Physiol (C), Sifi (C)

Dr Browning: Aerpio Therapeutics (S), Alimera Sciences (C), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr Buznego: Alcon Laboratories (C, L), Allergan (C, L), Bausch + Lomb (C, L), Calhoun Vision (O), CXL Ophthalmics (O), CXLUSA (O), Glaukos Corporation (C, L, O, S), LENSAR (C, L), Omeros (C, L), Rapid Pathogen Screening (O)

Dr Cochener-Lamard: Abbott Medical Optics (C, L), Alcon Laboratories (C, L), Bausch + Lomb (S), Horus (C, L), Physiol (C, L), ReVision Optics (C, L), Santen (C, L), Théa (C, L)

Dr Fouraker: Addition Technology (C, L), Alcon Laboratories (C, L), KeraVision (C, L), OASIS Medical (C, L)

Dr Grosser: Ivantis (O)

Dr Isbey: Alcon Laboratories (S), Bausch + Lomb (S)

Dr Nagy: Alcon Laboratories (C, L)

Dr Roberts: Abbott Medical Optics (C), Alcon Laboratories (C, L), Allergan (C), Device Technologies (C), Pfizer (C, L)

Dr Savage: Allergan (L)

Dr Tassignon: Morcher GmbH (P)

The other authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

\*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

## **Recent Past Faculty**

James C. Bobrow, MD

Joseph A. Reich, MBBS

Lisa F. Rosenberg, MD

Michael N. Wiggins, MD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

## **American Academy of Ophthalmology Staff**

Dale E. Fajardo, *Vice President, Education*

Beth Wilson, *Director, Continuing Professional Development*

Ann McGuire, *Acquisitions and Development Manager*

Stephanie Tanaka, *Publications Manager*

D. Jean Ray, *Production Manager*

Kimberly Torgerson, *Publications Editor*

Beth Collins, *Medical Editor*

Naomi Ruiz, *Publications Specialist*

American Academy of Ophthalmology  
655 Beach Street  
Box 7424  
San Francisco, CA 94120-7424



# Contents

|  |           |
|--|-----------|
| General Introduction . . . . .                                   | xv        |
| <b>Objectives</b> . . . . .                                      | <b>1</b>  |
| <b>Introduction</b> . . . . .                                    | <b>3</b>  |
| <b>1 Epidemiology of Cataract</b> . . . . .                      | <b>5</b>  |
| Introduction . . . . .   | 5         |
| Rate of Cataract Surgery . . . . .                               | 5         |
| Distribution of Cataract Subtypes . . . . .                      | 6         |
| Risk Factors for the Development of Cataract . . . . .           | 6         |
| <b>2 Anatomy</b> . . . . .                                       | <b>9</b>  |
| Normal Crystalline Lens . . . . .                                | 9         |
| Capsule . . . . .  | 11        |
| Zonular Fibers . . . . .   | 12        |
| Lens Epithelium . . . . .  | 12        |
| Nucleus and Cortex . . . . .                                     | 13        |
| <b>3 Biochemistry and Physiology</b> . . . . .                   | <b>15</b> |
| Molecular Biology . . . . .                                      | 15        |
| Crystallin Proteins . . . . .                                    | 15        |
| Membrane Structural Proteins and Cytoskeletal Proteins . . . . . | 16        |
| Increase of Water-Insoluble Proteins With Age . . . . .          | 17        |
| Carbohydrate Metabolism . . . . .                                | 17        |
| Oxidative Damage and Protective Mechanisms . . . . .             | 19        |
| Lens Physiology . . . . .  | 20        |
| Maintenance of Lens Water and Cation Balance . . . . .           | 21        |
| Accommodation and Presbyopia . . . . .                           | 22        |
| <b>4 Embryology and Developmental Defects</b> . . . . .          | <b>25</b> |
| Normal Development of the Lens . . . . .                         | 25        |
| Lens Placode . . . . .   | 25        |
| Lens Pit . . . . .   | 25        |
| Lens Vesicle . . . . .   | 25        |
| Primary Lens Fibers and the Embryonic Nucleus . . . . .          | 26        |
| Secondary Lens Fibers . . . . .                                  | 27        |
| Lens Sutures and the Fetal Nucleus . . . . .                     | 28        |
| Tunica Vasculosa Lentis . . . . .                                | 29        |
| The Zonule of Zinn . . . . .                                     | 29        |
| Congenital Anomalies and Abnormalities . . . . .                 | 30        |
| Congenital Aphakia . . . . .                                     | 30        |
| Lenticonus and Lentiglobus . . . . .                             | 30        |

|   |           |
|---|-----------|
| Lens Coloboma . . . . .                                 | 30        |
| Mittendorf Dot . . . . .                                | 31        |
| Epicapsular Star. . . . .                               | 31        |
| Peters Anomaly . . . . .                                | 31        |
| Microspherophakia . . . . .                             | 32        |
| Aniridia . . . . .                                      | 33        |
| Congenital Cataract . . . . .                           | 34        |
| Developmental Defects . . . . .                         | 39        |
| Ectopia Lentis . . . . .                                | 39        |
| Genetic Contributions to Age-Related Cataracts. . . . . | 41        |
| Ectopia Lentis et Pupillae. . . . .                     | 42        |
| Persistent Fetal Vasculature. . . . .                   | 42        |
| <b>5 Pathology . . . . .</b>                            | <b>43</b> |
| Age-Related Lens Changes . . . . .                      | 43        |
| Nuclear Cataracts . . . . .                             | 43        |
| Cortical Cataracts . . . . .                            | 45        |
| Posterior Subcapsular Cataracts . . . . .               | 46        |
| Drug-Induced Lens Changes . . . . .                     | 51        |
| Corticosteroids . . . . .                               | 51        |
| Phenothiazines . . . . .                                | 52        |
| Miotics . . . . .                                       | 52        |
| Amiodarone . . . . .                                    | 53        |
| Statins . . . . .                                       | 53        |
| Tamoxifen . . . . .                                     | 53        |
| Trauma . . . . .  | 53        |
| Contusion . . . . .                                     | 53        |
| Perforating or Penetrating Injury . . . . .             | 55        |
| Intraocular Procedures. . . . .                         | 55        |
| Intralenticular Foreign Bodies . . . . .                | 57        |
| Radiation . . . . .                                     | 57        |
| Metallosis . . . . .                                    | 58        |
| Electrical Injury. . . . .                              | 59        |
| Chemical Injuries . . . . .                             | 59        |
| Metabolic Cataract . . . . .                            | 60        |
| Diabetes Mellitus . . . . .                             | 60        |
| Galactosemia. . . . .                                   | 61        |
| Hypocalcemia . . . . .                                  | 61        |
| Wilson Disease . . . . .                                | 62        |
| Myotonic Dystrophy. . . . .                             | 62        |
| Effects of Nutrition, Alcohol, and Smoking. . . . .     | 63        |
| Cataract Associated With Uveitis . . . . .              | 64        |
| Lens Changes With Hyperbaric Oxygen Therapy . . . . .   | 65        |
| Pseudoexfoliation Syndrome . . . . .                    | 65        |
| Cataract and Atopic Dermatitis. . . . .                 | 66        |
| Phacoantigenic Uveitis . . . . .                        | 66        |

|   |           |
|---|-----------|
| Lens-Induced Glaucoma . . . . .                                     | 67        |
| Phacolytic Glaucoma . . . . .                                       | 67        |
| Lens Particle Glaucoma . . . . .                                    | 67        |
| Phacomorphic Glaucoma . . . . .                                     | 67        |
| Glaukomflecken . . . . .  | 68        |
| Ischemia . . . . .  | 68        |
| Cataracts Associated With Degenerative Ocular Disorders . . . . .   | 68        |
| <b>6 Evaluation and Management of Cataracts in Adults . . . . .</b> | <b>69</b> |
| Clinical History: Signs and Symptoms . . . . .                      | 69        |
| Decreased Visual Acuity . . . . .                                   | 69        |
| Glare and Altered Contrast Sensitivity . . . . .                    | 70        |
| Myopic Shift . . . . .  | 70        |
| Monocular Diplopia or Polyopia . . . . .                            | 70        |
| Decreased Visual Function . . . . .                                 | 71        |
| Nonsurgical Management . . . . .                                    | 71        |
| Indications for Surgery . . . . .                                   | 72        |
| Preoperative Evaluation . . . . .                                   | 74        |
| General Health of the Patient . . . . .                             | 74        |
| Pertinent Ocular History . . . . .                                  | 75        |
| Social History . . . . .  | 76        |
| Measurements of Visual Function . . . . .                           | 76        |
| Visual Acuity Testing . . . . .                                     | 76        |
| Refraction . . . . .  | 76        |
| Glare Testing . . . . .   | 77        |
| Contrast Sensitivity Testing . . . . .                              | 77        |
| External Examination . . . . .                                      | 77        |
| Motility . . . . .  | 77        |
| Pupils . . . . .  | 78        |
| Slit-Lamp Examination . . . . .                                     | 78        |
| Conjunctiva . . . . .   | 78        |
| Cornea . . . . .  | 78        |
| Anterior Chamber and Iris . . . . .                                 | 79        |
| Crystalline Lens . . . . .  | 79        |
| Limitations of Slit-Lamp Examination . . . . .                      | 80        |
| Fundus Evaluation . . . . .   | 80        |
| Ophthalmoscopy . . . . .  | 80        |
| Optic Nerve . . . . .   | 81        |
| Fundus Evaluation With Opaque Media . . . . .                       | 81        |
| Special Tests . . . . .   | 81        |
| Potential Acuity Estimation . . . . .                               | 81        |
| Visual Field Testing . . . . .                                      | 82        |
| Objective Tests of Macular Function . . . . .                       | 82        |
| Preoperative Measurements . . . . .                                 | 82        |
| Biometry . . . . .  | 82        |
| Corneal Topography . . . . .  | 84        |
| Additional Evaluation of the Cornea . . . . .                       | 84        |

|  |           |
|--|-----------|
| IOL Power Determination . . . . .  | 84        |
| IOL Calculation . . . . .  | 85        |
| Preventing Errors in IOL Calculation, Selection, and Insertion . . . . .         | 87        |
| Improving Outcomes . . . . .   | 87        |
| Patient Preparation and Informed Consent . . . . .                               | 87        |
| <b>7 Surgery for Cataract . . . . .</b>  | <b>89</b> |
| Historical Overview of Cataract Surgery . . . . .                                | 89        |
| Anesthesia for Cataract Surgery . . . . .  | 91        |
| Antimicrobial Prophylaxis . . . . .  | 93        |
| Before Surgery . . . . .   | 93        |
| In Surgery . . . . .   | 94        |
| After Surgery . . . . .  | 95        |
| Ophthalmic Viscosurgical Devices . . . . .                                       | 95        |
| Physical Properties . . . . .  | 96        |
| Uses of Ophthalmic Viscosurgical Devices . . . . .                               | 97        |
| Phacoemulsification: Instrumentation, Terminology,<br>and Key Concepts . . . . . | 98        |
| Instrumentation . . . . .  | 98        |
| Ultrasonic Technology Terminology . . . . .                                      | 99        |
| Key Concepts and Advances in Phaco Power Delivery . . . . .                      | 100       |
| Irrigation . . . . .   | 101       |
| Fluidics and Phacodynamics Terminology . . . . .                                 | 102       |
| Aspiration Pumps . . . . .   | 103       |
| Outline of the Phacoemulsification Procedure . . . . .                           | 104       |
| Eye Marking and Time-Out . . . . .   | 104       |
| Exposure of the Globe . . . . .  | 105       |
| Paracentesis . . . . .   | 105       |
| Clear Corneal Incision . . . . .   | 106       |
| Scleral Tunnel Incision . . . . .  | 107       |
| Continuous Curvilinear Capsulorrhesis . . . . .                                  | 108       |
| Hydrodissection . . . . .  | 110       |
| Hydrodelineation . . . . .   | 110       |
| Nucleus Rotation . . . . .   | 111       |
| Nucleus Disassembly and Removal . . . . .  | 111       |
| Location of Emulsification . . . . .   | 111       |
| Techniques of Nucleus Disassembly . . . . .                                      | 112       |
| Irrigation and Aspiration . . . . .  | 115       |
| Insertion of the IOL . . . . .   | 115       |
| After IOL Insertion . . . . .  | 117       |
| IOLs: Historical Perspectives and Lens Modifications . . . . .                   | 118       |
| Historical Perspectives . . . . .  | 118       |
| Posterior Chamber IOLs and Other Lens Modifications . . . . .                    | 119       |
| Modification of Preexisting Astigmatism . . . . .                                | 123       |
| Astigmatic Keratotomy . . . . .  | 123       |
| Limbal Relaxing Incisions . . . . .  | 123       |
| Toric IOLs . . . . .   | 124       |

|  |            |
|--|------------|
| Alternative Technologies for Cataract Extraction . . . . . | 125        |
| Laser Photolysis . . . . .                                 | 125        |
| Fluid-Based Phacolysis . . . . .                           | 125        |
| Femtosecond Laser Cataract Extraction . . . . .            | 125        |
| Outcomes of Cataract Surgery . . . . .                     | 126        |
| <b>8 Complications of Cataract Surgery . . . . .</b>       | <b>127</b> |
| Corneal Complications . . . . .                            | 128        |
| Corneal Edema . . . . .                                    | 128        |
| Incision and Wound Complications . . . . .                 | 130        |
| Descemet Membrane Detachment . . . . .                     | 131        |
| Induced Astigmatism . . . . .                              | 131        |
| Corneal Melting . . . . .                                  | 132        |
| Other Anterior Segment Complications . . . . .             | 132        |
| Epithelial or Fibrous Ingrowth . . . . .                   | 132        |
| Toxic Anterior Segment Syndrome . . . . .                  | 133        |
| Shallow or Flat Anterior Chamber . . . . .                 | 134        |
| Elevated Intraocular Pressure . . . . .                    | 136        |
| Intraoperative Floppy Iris Syndrome . . . . .              | 136        |
| Lens–Iris Diaphragm Retropulsion Syndrome . . . . .        | 138        |
| Iridodialysis and Iris Trauma . . . . .                    | 138        |
| Cyclodialysis . . . . .                                    | 139        |
| Ciliary Block Glaucoma . . . . .                           | 139        |
| Postoperative Uveitis . . . . .                            | 139        |
| Retained Lens Material . . . . .                           | 140        |
| Capsular Rupture . . . . .                                 | 142        |
| Vitreous Prolapse in the Anterior Chamber . . . . .        | 143        |
| Complications of IOL Implantation . . . . .                | 144        |
| Decentration and Dislocation . . . . .                     | 144        |
| Pupillary Capture . . . . .                                | 148        |
| Capsular Block Syndrome . . . . .                          | 148        |
| Uveitis-Glaucoma-Hyphema Syndrome . . . . .                | 149        |
| Pseudophakic Bullous Keratopathy . . . . .                 | 149        |
| Unexpected Refractive Results . . . . .                    | 149        |
| IOL Glare, Dysphotopsia, and Opacification . . . . .       | 150        |
| Capsular Opacification and Contraction . . . . .           | 152        |
| Posterior Capsule Opacification . . . . .                  | 152        |
| Anterior Capsule Fibrosis and Phimosis . . . . .           | 153        |
| Nd:YAG Laser Capsulotomy . . . . .                         | 154        |
| Hemorrhage . . . . .                                       | 157        |
| Systemic Anticoagulation . . . . .                         | 157        |
| Retrobulbar Hemorrhage . . . . .                           | 158        |
| Hyphema . . . . .  | 158        |
| Suprachoroidal Effusion or Hemorrhage . . . . .            | 159        |
| Expulsive Suprachoroidal Hemorrhage . . . . .              | 159        |
| Delayed Suprachoroidal Hemorrhage . . . . .                | 160        |

|   |            |
|---|------------|
| Endophthalmitis . . . . .   | 160        |
| Diagnosis . . . . .   | 162        |
| Treatment . . . . .   | 162        |
| Retinal Complications. . . . .  | 163        |
| Cystoid Macular Edema . . . . .   | 163        |
| Retinal Light Toxicity . . . . .  | 166        |
| Retinal Detachment . . . . .  | 166        |
| <b>9 Preparing for Cataract Surgery in Special Situations . . . . .</b> | <b>169</b> |
| Psychosocial Considerations . . . . .                                   | 169        |
| Claustrophobia . . . . .  | 169        |
| Neurocognitive and Neurodevelopmental Disorders . . . . .               | 169        |
| Patient Communication During Eye Surgery . . . . .                      | 170        |
| Systemic Considerations. . . . .  | 170        |
| Medical Status . . . . .  | 170        |
| Anticoagulation Therapy or Bleeding Disorders . . . . .                 | 171        |
| External Ocular Abnormalities . . . . .                                 | 172        |
| Blepharitis and Acne Rosacea . . . . .                                  | 172        |
| Keratoconjunctivitis Sicca . . . . .                                    | 173        |
| Mucous Membrane Pemphigoid . . . . .                                    | 173        |
| Exposure Keratitis and Seventh Nerve Palsy . . . . .                    | 174        |
| Corneal Conditions. . . . .   | 174        |
| Corneal Disease . . . . .   | 174        |
| Cataract and Keratoplasty . . . . .                                     | 175        |
| Cataract Following Keratoplasty. . . . .                                | 176        |
| Cataract Following Refractive Surgery . . . . .                         | 176        |
| Compromised Visualization of the Lens . . . . .                         | 177        |
| Small Pupil. . . . .  | 177        |
| Poor Red Reflex. . . . .  | 178        |
| Altered Lens and Zonular Anatomy . . . . .                              | 179        |
| Intumescent Cataract . . . . .  | 179        |
| Advanced Cataract . . . . .   | 180        |
| Iris Coloboma and Corectopia . . . . .                                  | 180        |
| Posterior Polar Cataract . . . . .                                      | 180        |
| Zonular Dehiscence With Lens Subluxation or Dislocation . . . . .       | 181        |
| Pseudoexfoliation Syndrome . . . . .                                    | 184        |
| Cataract in Aniridia . . . . .  | 184        |
| Conditions Associated With Extremes in Axial Length. . . . .            | 184        |
| High Myopia . . . . .   | 184        |
| High Hyperopia and Nanophthalmos . . . . .                              | 185        |
| Hypotony . . . . .  | 185        |
| Glaucoma and Cataract . . . . .   | 186        |
| Assessment. . . . .   | 186        |
| Cataract Surgery in an Eye With a Functioning Filter . . . . .          | 187        |
| Uveitis . . . . .   | 188        |

|   |     |
|---|-----|
| Retinal Conditions . . . . .  | 189 |
| Retinal Disease . . . . .   | 189 |
| Cataract Following Pars Plana Vitrectomy . . . . .                    | 190 |
| Cataract With Intraocular Silicone Oil . . . . .                      | 190 |
| Ocular Trauma . . . . .   | 190 |
| Ocular Assessment . . . . .   | 190 |
| Visualization During Surgery . . . . .                                | 191 |
| Inflammation . . . . .  | 191 |
| Retained Foreign Matter . . . . .                                     | 191 |
| Cataract in an Eye With Damage to Other Ocular Tissues . . . . .      | 191 |
| Removal of Traumatic Cataract . . . . .                               | 192 |
| Vision Rehabilitation . . . . .                                       | 193 |
| IOL Selection After Trauma . . . . .                                  | 193 |
| <br>Appendix: Surgical Procedures for Extracapsular and Intracapsular |     |
| Cataract Extraction . . . . .   | 195 |
| Basic Texts . . . . .   | 203 |
| Related Academy Materials . . . . .                                   | 205 |
| Requesting Continuing Medical Education Credit . . . . .              | 207 |
| Study Questions . . . . .   | 209 |
| Answer Sheet for Section 11 Study Questions . . . . .                 | 215 |
| Answers . . . . .   | 217 |
| Index . . . . .   | 223 |



# General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

## Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

- 1 Update on General Medicine
- 2 Fundamentals and Principles of Ophthalmology
- 3 Clinical Optics
- 4 Ophthalmic Pathology and Intraocular Tumors
- 5 Neuro-Ophthalmology
- 6 Pediatric Ophthalmology and Strabismus
- 7 Orbit, Eyelids, and Lacrimal System
- 8 External Disease and Cornea
- 9 Intraocular Inflammation and Uveitis
- 10 Glaucoma
- 11 Lens and Cataract
- 12 Retina and Vitreous
- 13 Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

## References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.

These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

## Videos

This edition of Section 11, *Lens and Cataract*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 11. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

## Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

## Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.

# Objectives

---

Upon completion of BCSC Section 11, *Lens and Cataract*, the reader should be able to

- describe the normal anatomy, embryologic development, physiology, and biochemistry of the crystalline lens
  - identify congenital anomalies of the lens
  - list types of congenital and acquired cataracts
  - describe the association of cataracts with aging, trauma, medications, and systemic and ocular diseases
  - describe the evaluation and management of patients with cataract and other lens abnormalities
  - state the principles of cataract surgery techniques and associated surgical technology
  - describe an appropriate differential diagnosis and management plan for intraoperative and postoperative complications of cataract surgery
  - identify special circumstances in which cataract surgery techniques should be modified, and describe appropriate treatment plans
-